Department of Gynaecological Oncology Publications

Publications 2025

1. Bjerre Trent P, Eriksson AG, Staff AC, Juul-Hansen KE, Burger EA, Wangen KR (2025)
   A cost-effectiveness analysis of sentinel lymph node biopsy compared with lymphadenectomy in intermediate- and high-risk endometrial carcinoma
   Int J Gynecol Cancer (in press)
   DOI 10.1136/ijgc-2024-005906, PubMed 39433423
2. Bjerre Trent P, Leitzinger N, Wang Y, Dahl GF, Eyjólfsdóttir B, Dahl JF, Lund KV, Staff AC, Falk RS, Eriksson AGZ (2025)
   The detection rate of metastatic lymph nodes comparing sentinel lymph node biopsy and lymphadenectomy for staging of intermediate- and high-risk endometrial carcinoma
   Int J Gynecol Cancer, 35 (5), 101810
   DOI 10.1016/j.ijgc.2025.101810, PubMed 40288097
3. Brunetti M, Vitelli V, Naas AM, Zahl Eriksson AG, Haugland HK, Krakstad C, Micci F (2025)
   Molecular Landscape of Endometrial Stromal Tumors
   JCO Precis Oncol, 9, e2400779
   DOI 10.1200/PO-24-00779, PubMed 40403211
4. Costa J, Le VL, De Leo A, Ravaioli C, Velasco V, Davidson B, Skeie-Jensen T, Devouassoux-Shisheboran M, Trecourt A, Bartosch C, Rios E, Genestie C, Pautier P, Lebreton C, Guyon F, Babin G, Coindre JM, Le Loarer F, Saut O, Croce S (2025)
   Deep learning can accurately predict the prognosis of gynecologic smooth muscle tumors of uncertain malignant potential: a multicenter pilot study
   Lab Invest, 104211 (in press)
   DOI 10.1016/j.labinv.2025.104211, PubMed 40602459
5. Dagher C, Bjerre Trent P, Alwaqfi R, Davidson B, Ellenson LH, Zhou Q, Iasonos A, Mueller JJ, Alektiar K, Makker V, Feinberg J, Smith E, Kim SH, Hatoum S, Leitao MM, Abu-Rustum NR, Eriksson AGZ (2025)
   Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma
   Int J Gynecol Cancer, 35 (4), 101651
   DOI 10.1016/j.ijgc.2025.101651, PubMed 40055122
6. Dagher C, Trent PB, Alwaqfi R, Davidson B, Ellenson LH, Zhou Q, Iasonos A, Mueller JJ, Alektiar K, Makker V, Feinberg J, Smith E, Kim SH, Hatoum S, Leitao MM, Abu-Rustum NR, Eriksson AGZ (2025)
   Erratum to 'Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma' [International Journal of Gynecological Cancer Volume 35 Issue 4 (2025) 101651]
   Int J Gynecol Cancer, 101962 (in press)
   DOI 10.1016/j.ijgc.2025.101962, PubMed 40483226
7. Engh A, Rueegg CS, Bjerre Trent PK, Opheim LØ, Engeskaug I, Nordskar NJ, Bakken A, Steene-Johannessen J, Eriksson AGZ, Thorsen L (2025)
   Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study
   Gynecol Oncol, 195, 82-88
   DOI 10.1016/j.ygyno.2025.03.009, PubMed 40086214
8. Falkenthal TEH (2025)
   [Not Available]
   Tidsskr Nor Laegeforen, 145 (3)
   DOI 10.4045/tidsskr.25.0040, PubMed 40042025
9. Haug AJ, Støer N, Langseth H, Siafarikas F, Botteri E, Fortner RT, Lindemann K (2025)
   Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study
   Int J Cancer, 157 (2), 277-287
   DOI 10.1002/ijc.35363, PubMed 39992017
10. Hillemanns P, Zikan M, Forget F, Denys HG, Baurain JF, Rob L, Woelber L, Blecharz P, Bidzinski M, Chovanec J, Marmé F, Link T, Dannecker C, Rosholm A, Berg KCG, Oliveri RS, Lindemann K, VB C-02 investigators, VB C-02 study (2025)
    Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study
    J Immunother Cancer, 13 (1)
    DOI 10.1136/jitc-2024-010827, PubMed 39773564
11. Lindemann K, Berton D, Sehouli J, Christensen RD, Altintas S, Knudsen AØ, Heudel PE, Ataseven B, Vergote I, Lindahl G, Lebreton C, Schochter F, Auranen A, Follana P, Madsen K, Selle F, Petersson KS, Joly F, Braicu EI, Mirza MR (2025)
    NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer
    Gynecol Oncol, 199, 79-87 (in press)
    DOI 10.1016/j.ygyno.2025.06.008, PubMed 40592025
12. Lindemann K, Siegenthaler F, Lande KT, Casas-Arozamena C, Nebdal D, Rau TT, Hoivik EA, Mueller MD, Gold RM, Imboden S, Davidson B, Krakstad C, Sørlie T (2025)
    Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study
    Gynecol Oncol, 195, 98-105
    DOI 10.1016/j.ygyno.2025.03.002, PubMed 40081113
13. Meltzer-Gunnes CJ, Hagen MC, Wang Y, Jensen PT, Vistad I (2025)
    Long-term quality of life, vulvar symptoms, and sexual functioning: A cross-sectional study of Norwegian vulvar cancer survivors
    Acta Obstet Gynecol Scand (in press)
    DOI 10.1111/aogs.15155, PubMed 40366224
14. Poveda A, Lheureux S, Colombo N, Cibula D, Elstrand M, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Rubio Pérez MJ, Ledermann J, Romero I, Özgören O, Barnicle A, Marshall H, Bashir Z, Škof E (2025)
    Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial
    Gynecol Oncol, 197, 74-82
    DOI 10.1016/j.ygyno.2025.04.580, PubMed 40300425
15. Pradhan M, Kildal W, Vlatkovic L, Tobin KAR, Lindemann K, Kristensen GB, Kleppe A, Askautrud HA (2025)
    Prognostic value of tertiary lymphoid structures in molecular subgroups of endometrial carcinoma
    Int J Gynecol Cancer, 35 (7), 101915 (in press)
    DOI 10.1016/j.ijgc.2025.101915, PubMed 40409205
16. Pradhan M, Kildal W, Vlatkovic L, Tobin KAR, Lindemann K, Kristensen GB, Kleppe A, Askautrud HA (2025)
    Response to correspondence on prognostic value of tertiary lymphoid structures in molecular subgroups of endometrial carcinoma by Pradhan et al
    Int J Gynecol Cancer, 35 (7), 101970 (in press)
    DOI 10.1016/j.ijgc.2025.101970, PubMed 40592175
17. Skipar K, Hompland T, Lund KV, Fjeldbo CS, Lindemann K, Hellebust TP, Lyng H, Bruheim K (2025)
    Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: A phase II, randomized study
    Acta Oncol, 64, 439-447
    DOI 10.2340/1651-226X.2025.43045, PubMed 40105683
18. Støer NC, Botteri E, Lindemann K, Langseth H, Fortner RT (2025)
    Low-dose aspirin and non-aspirin non-steroidal anti-inflammatory drugs and epithelial ovarian cancer survival: a registry-based cohort study in Norway
    BMC Cancer, 25 (1), 807
    DOI 10.1186/s12885-025-14168-y, PubMed 40307814
19. Trewin-Nybråten CB, Leithe S, Paulsen T, Langseth H, Fortner RT (2025)
    Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway
    Br J Cancer, 132 (12), 1158-1166
    DOI 10.1038/s41416-025-03018-0, PubMed 40287590

Publications 2024

1. Angeles MA, Agusti N, Bonaldo G, Bizzarri N, Bilir E, Piedimonte S, Olearo E, Navarro Santana B, Sahin Aker S, El Hajj H, Ghirardi V, Kacperczyk-Bartnik J, Strojna AN, Fotopoulou C, Plante M, Lorusso D, Cibula D, Lindemann K, Scambia G, McCormack M, Leitao M, Fagotti A, Concin N, Martinez A, Ramirez PT (2024)
   Highlights from the 25th European Congress on Gynaecological Oncology in Barcelona: the ENYGO-IJGC Fellow Interviews
   Int J Gynecol Cancer, 34 (10), 1522-1528
   DOI 10.1136/ijgc-2024-005704, PubMed 39181697
2. Areklett EW, Hagen BI, Stubberud J, Fagereng E, Andersson S, Lindemann K (2024)
   Digital goal management training for cognitive impairment in cervical cancer survivors-a randomized comparison study
   J Cancer Surviv (in press)
   DOI 10.1007/s11764-024-01701-4, PubMed 39576570
3. Birgisdóttir A, Myklebust TÅ, Bjørnslett M, Rognlien VW, Paulsen T, Dørum A (2024)
   BRCA mutation testing and association with oncologic outcome and incidence of ovarian cancer in Norway
   Int J Gynecol Cancer, 35 (2), 100029
   DOI 10.1016/j.ijgc.2024.100029, PubMed 39971428
4. Bischof K, Cremaschi A, Eroukhmanoff L, Landskron J, Flage-Larsen LL, Gade A, Bjørge L, Urbanucci A, Taskén K (2024)
   Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
   Mol Oncol, 19 (1), 81-98
   DOI 10.1002/1878-0261.13726, PubMed 39245677
5. Bischof K, Holth A, Bassarova A, Davidson B (2024)
   Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression
   Pathol Res Pract, 266, 155787
   DOI 10.1016/j.prp.2024.155787, PubMed 39709875
6. Bjerre Trent PK, Nordskar NJ, Wangen KR, Engeskaug MI, Opheim MLØ, Aune G, Staff AC, Thorsen L, Falk RS, Eriksson AGZ (2024)
   Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80]
   Gynecol Oncol, 183, 7-8
   DOI 10.1016/j.ygyno.2024.02.026, PubMed 38484693
7. Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S (2024)
   Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
   J Immunother Cancer, 12 (4)
   DOI 10.1136/jitc-2023-008179, PubMed 38604812
8. Cun HT, Bernard L, Lande KT, Lawson BC, Nesbakken AJ, Davidson B, Lindemann K, Fellman B, Sørlie T, Soliman PT, Eriksson AGZ (2024)
   Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
   Gynecol Oncol, 189, 138-145
   DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895
9. Dagher C, Bjerre Trent P, Alwaqfi R, Davidson B, Ellenson L, Zhou QC, Iasonos A, Mueller JJ, Alektiar K, Makker V, Kim S, Leitao MM, Abu-Rustum NR, Eriksson AGZ (2024)
   Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
   Int J Gynecol Cancer, 34 (10), 1485-1492
   DOI 10.1136/ijgc-2024-005746, PubMed 39074932
10. Davidson B, Holth A, Lindemann K, Zahl Eriksson AG, Nilsen TA, Torgunrud A (2024)
    Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
    Virchows Arch, 485 (6), 1053-1061
    DOI 10.1007/s00428-024-03821-9, PubMed 38733380
11. Davidson B, Skeie-Jensen T, Holth A, Hausladen S (2024)
    Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
    Int J Gynecol Pathol, 44 (1), 56-66
    DOI 10.1097/PGP.0000000000001030, PubMed 38847524
12. Davidson B, Teien Lande K, Nebdal D, Nesbakken AJ, Holth A, Lindemann K, Zahl Eriksson AG, Sørlie T (2024)
    Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
    Virchows Arch, 486 (4), 697-705
    DOI 10.1007/s00428-024-03912-7, PubMed 39235515
13. Denschlag D, Heitz F, Pfisterer J, Tutschkow D, Reuss A, Meier W, Harter P, Wimberger P, Mirza MR, Ray-Coquard I, Scambia G, Kim JW, Colombo N, Oaknin A, Sehouli J, Lindemann K, Lebreton C, Eichbaum M, Spiegelberg S, Woopen H, du Bois A (2024)
    Impact of metformin, statins, and beta blockers on survival in patients with primary ovarian cancer: combined analysis of four prospective trials of AGO-OVAR and ENGOT/GCIG collaborators
    Int J Gynecol Cancer, 34 (12), 1914-1923
    DOI 10.1136/ijgc-2024-005663, PubMed 39322609
14. Ferguson SE, Brotto LA, Kwon J, Samouelian V, Ferron G, Maulard A, Kroon C, Driel WV, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjolfsdottir B, Kim JW, Gleeson N, Tu D, Shepherd L, Plante M (2024)
    Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
    J Clin Oncol, 43 (2), 167-179
    DOI 10.1200/JCO.24.00440, PubMed 39353164
15. Fotopoulou C, Eriksson AG, Baiocchi G, Zivanovic O (2024)
    Surgery for gynecological cancers in the era of personalized medicine: a novel paradigm
    Int J Gynecol Cancer, 34 (3), 351
    DOI 10.1136/ijgc-2024-005299, PubMed 38438173
16. Fotopoulou C, Eriksson AG, Planchamp F, Morice P, Taylor A, Sturdza A, Florin Coza O, Halaska MJ, Martinelli F, Armbrust R, Chargari C (2024)
    European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management
    Int J Gynecol Cancer, 34 (4), 480-490
    DOI 10.1136/ijgc-2024-005293, PubMed 38395448
17. Kleppe A, Lindemann K, Kildal W, Tobin KAR, Pradhan M, Vlatkovic L, Isaksen MX, Danielsen HE, Askautrud HA, Kristensen GB (2024)
    Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer
    Gynecol Oncol, 192, 80-88
    DOI 10.1016/j.ygyno.2024.11.005, PubMed 39549540
18. Krakstad C, Berg HF, Lindemann K, Halle MK (2024)
    Frequency of ERBB2-Low Expression in Endometrial Cancer
    JAMA Oncol, 10 (11), 1587-1588
    DOI 10.1001/jamaoncol.2024.3660, PubMed 39235791
19. Kwon JS, McTaggart-Cowan H, Ferguson SE, Samouëlian V, Lambaudie E, Guyon F, Tidy J, Williamson K, Gleeson N, de Kroon C, van Driel W, Mahner S, Hanker L, Goffin F, Berger R, Eyjólfsdóttir B, Kim JW, Brotto LA, Pataky R, Yeung SST, Chan KKW, Cheung MC, Ubi J, Tu D, Shepherd LE et al. (2024)
    Cost-effectiveness analysis of simple hysterectomy compared to radical hysterectomy for early cervical cancer: analysis from the GCIG/CCTG CX.5/SHAPE trial
    J Gynecol Oncol, 35 (6), e117
    DOI 10.3802/jgo.2024.35.e117, PubMed 39453395
20. La Russa M, Zapardiel I, Zalewski K, Laky R, Dursun P, Sukhin V, Lindquist D, Lindemann K (2024)
    Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members
    BMJ Support Palliat Care, 15 (1), 104-107
    DOI 10.1136/bmjspcare-2020-002233, PubMed 32958506
21. Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marmé F, Marth C et al. (2024)
    ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
    Ann Oncol, 35 (3), 248-266
    DOI 10.1016/j.annonc.2023.11.015, PubMed 38307807
22. Lindemann K, Kildal W, Kleppe A, Tobin KAR, Pradhan M, Isaksen MX, Vlatkovic L, Danielsen HE, Kristensen GB, Askautrud HA (2024)
    Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer
    Eur J Cancer, 200, 113584
    DOI 10.1016/j.ejca.2024.113584, PubMed 38330767
23. Lindemann K, Kildal W, Kleppe A, Tobin KAR, Pradhan M, Mascialino B, Schneider D, Edvardsen H, Sørlie T, Kristensen GB, Askautrud HA (2024)
    Real-world outcomes in molecular subgroups for patients with advanced or recurrent endometrial cancer treated with platinum-based chemotherapy
    Int J Gynecol Cancer, 35 (5), 101618
    DOI 10.1016/j.ijgc.2024.101618, PubMed 40189984
24. Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A et al. (2024)
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
    Lancet, 404 (10460), 1321-1332
    DOI 10.1016/S0140-6736(24)01808-7, PubMed 39288779
25. Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A et al. (2024)
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
    Lancet, 403 (10434), 1341-1350
    DOI 10.1016/S0140-6736(24)00317-9, PubMed 38521086
26. Luijten MMW, van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Krakstad C, Witteveen PO, Galaal K, van Ginkel AA, Bignotti E, Weinberger V, Sweegers S, Eriksson AGZ, Keizer DM, van de Stolpe A, Romano A, Pijnenborg JMA, European Network For Individualized Treatment In Endometrial Cancer (2024)
    Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
    Cancers (Basel), 16 (11)
    DOI 10.3390/cancers16112084, PubMed 38893205
27. Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J (2024)
    Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial
    Gynecol Oncol, 192, 128-136
    DOI 10.1016/j.ygyno.2024.12.003, PubMed 39657575
28. Mirza MR, Tandaric L, Henriksen JR, Mäenpää J, Christensen RD, Waldstrøm M, Lindemann K, Roed H, Auranen A, Akslen LA, Thomsen LCV, Lindberg SN, Madsen K, Bjørge L (2024)
    NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer
    Gynecol Oncol, 188, 103-110
    DOI 10.1016/j.ygyno.2024.06.017, PubMed 38943691
29. Morice P, Scambia G, Abu-Rustum NR, Acien M, Arena A, Brucker S, Cheong Y, Collinet P, Fanfani F, Filippi F, Eriksson AGZ, Gouy S, Harter P, Matias-Guiu X, Pados G, Pakiz M, Querleu D, Rodolakis A, Rousset-Jablonski C, Stepanyan A, Testa AC, Macklon KT, Tsolakidis D, De Vos M, Planchamp F et al. (2024)
    Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE
    Lancet Oncol, 25 (11), e602-e610
    DOI 10.1016/S1470-2045(24)00262-6, PubMed 39216500
30. Nikolova T, Bilir E, Bizzarri N, Fotopoulou C, van Gorp T, Kacperczyk-Bartnik J, Razumova Z, Strojna AN, Eriksson AG, Pakiz M, Mirza MR, Fagotti A, Concin N (2024)
    Gender equality, diversity, and inclusion among gynaecologic oncologists: European Network of Young Gynae Oncologists (ENYGO)-European Society of Gynaecological Oncology (ESGO) project
    Int J Gynecol Cancer, 34 (11), 1685-1690
    DOI 10.1136/ijgc-2024-005697, PubMed 39395820
31. Os SS, Skipar K, Skovlund E, Hompland I, Hellebust TP, Guren MG, Lindemann K, Nakken ES (2024)
    Survival prediction in patients with gynecological cancer irradiated for brain metastases
    Acta Oncol, 63, 206-212
    DOI 10.2340/1651-226X.2023.34899, PubMed 38647023
32. Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, Tamussino K, Eyjólfsdóttir B, Kim JW, Gleeson N, Brotto L, Tu D, Shepherd LE, CX.5 SHAPE investigators, CX.5 SHAPE Investigators (2024)
    Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
    N Engl J Med, 390 (9), 819-829
    DOI 10.1056/NEJMoa2308900, PubMed 38416430
33. Plante M, Mahner S, Sebastianelli A, Bessette P, Lambaudie E, Guyon F, Piek J, Smolders R, Tidy J, Williamson K, Hanker L, Goffin F, Tsibulak I, Eyjolfsdottir B, Gleeson N, Lee JY, Ke Y, Kwon JS, Ferguson SE, Shepherd L, Tu D (2024)
    Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial
    Int J Gynecol Cancer, 35 (1), 100001
    DOI 10.1016/j.ijgc.2024.100001, PubMed 39878257
34. Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
    IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
    Acta Oncol, 63, 379-384
    DOI 10.2340/1651-226X.2024.28322, PubMed 38779911
35. Rios-Doria E, Abu-Rustum NR, Glaser G, McGree M, Eriksson AG, Pham M, Soliman P, Ataseven B, Alektiar K, Zamarin D, Leitao ML, Mueller J (2024)
    2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both
    Int J Gynecol Cancer, 34 (10), 1580-1587
    DOI 10.1136/ijgc-2024-005567, PubMed 39074930
36. Rios-Doria E, Nobre SP, Sassine D, Glaser G, Eriksson AG, Ataseven B, du Bois A, Makker V, Alektiar K, Leitao MM, Abu-Rustum NR, Mueller JJ (2024)
    Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium
    Gynecol Oncol, 190, 236-242
    DOI 10.1016/j.ygyno.2024.08.019, PubMed 39243699
37. Rostami S, Rounge TB, Pestarino L, Lyle R, Fortner RT, Haaland ØA, Lie RT, Wiklund F, Bjørge T, Langseth H (2024)
    Differential levels of circulating RNAs prior to endometrial cancer diagnosis
    Int J Cancer, 155 (5), 946-956
    DOI 10.1002/ijc.34951, PubMed 38733362
38. Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B et al. (2024)
    How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting
    Int J Gynecol Cancer, 34 (11), 1677-1684
    DOI 10.1136/ijgc-2024-005982, PubMed 39496422
39. Skipar K, Hompland T, Lund KV, Lindemann K, Hellebust TP, Bruheim K, Lyng H (2024)
    MRI-guided dynamic risk assessment in cervical cancer based on tumor hypoxia at diagnosis and volume response at brachytherapy
    Radiother Oncol, 195, 110263
    DOI 10.1016/j.radonc.2024.110263, PubMed 38556173
40. Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, Elias KM, Fendler W, Langseth H (2024)
    Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches
    Front Oncol, 14, 1389066
    DOI 10.3389/fonc.2024.1389066, PubMed 38983926
41. Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024)
    Evolutionary mode and timing of dissemination of high-grade serous carcinomas
    JCI Insight, 9 (3)
    DOI 10.1172/jci.insight.170423, PubMed 38175731
42. Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J et al. (2024)
    ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
    Ann Oncol, 35 (11), 968-980
    DOI 10.1016/j.annonc.2024.08.2242, PubMed 39284383

Publications 2023

1. Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N, Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee (2023)
   FIGO staging of endometrial cancer: 2023
   Int J Gynaecol Obstet, 162 (2), 383-394
   DOI 10.1002/ijgo.14923, PubMed 37337978
2. Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N, Endometrial Cancer Staging Subcommittee, FIGO Women's Cancer Committee (2023)
   FIGO staging of endometrial cancer: 2023
   J Gynecol Oncol, 34 (5), e85
   DOI 10.3802/jgo.2023.34.e85, PubMed 37593813
3. Bilir E, Ahmed W, Kacperczyk-Bartnik J, Nasser S, Bjerre Trent P, Boria F, Tsibulak I, Chacon E, Martinelli F, Strojna AN, Morgan G, Bizzarri N, Eriksson AG, Theofanakis C (2023)
   Social media ambassadors and collaboration with OncoAlert: a European Network of Young Gynae Oncologists study of comparative Twitter analysis of #ESGO2021 and #ESGO2022
   Int J Gynecol Cancer, 33 (6), 964-970
   DOI 10.1136/ijgc-2023-004371, PubMed 37130625
4. Bjerre Trent P, Falk RS, Staff AC, Jorde D, Eriksson AG (2023)
   Translation and cross-cultural adaptation of the Gynecologic Cancer Lymphedema Questionnaire and the Lower Extremity Lymphedema Screening Questionnaire
   Int J Gynecol Cancer, 33 (2), 231-235
   DOI 10.1136/ijgc-2022-003979, PubMed 36600491
5. Bjerre Trent PK, Nordskar NJ, Wangen KR, Engeskaug MI, Opheim MLØ, Aune G, Staff AC, Thorsen L, Falk RS, Eriksson AGZ (2023)
   Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study
   Gynecol Oncol, 175, 72-80
   DOI 10.1016/j.ygyno.2023.05.070, PubMed 37327542
6. Concin N, Matias-Guiu X, Fotopoulou C, Creutzberg C, Mutch D, Gaffney D, Lindemann K, Kehoe S, Berek JS, FIGO Committee on Women's Cancer (2023)
   Response: FIGO staging of endometrial cancer 2023
   Int J Gynaecol Obstet, 164 (1), 369-372
   DOI 10.1002/ijgo.15277, PubMed 38055215
7. Corbaux P, You B, Glasspool RM, Yanaihara N, Tinker AV, Lindemann K, Ray-Coquard IL, Mirza MR, Subtil F, Colomban O, Péron J, Karamouza E, McNeish I, Kelly C, Kagimura T, Welch S, Lewsley LA, Paoletti X, Cook A (2023)
   Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
   Eur J Cancer, 191, 112966
   DOI 10.1016/j.ejca.2023.112966, PubMed 37542936
8. Davidson B, Skeie-Jensen T, Holth A, Lindemann K, Toralba Barrameda AM, Lie AK, Wang Y (2023)
   Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
   Virchows Arch, 484 (6), 951-963
   DOI 10.1007/s00428-023-03670-y, PubMed 37843640
9. Davidson B, Solheim O (2023)
   Cancer Stem Cell Markers Are Differentially Expressed in Malignant Ovarian Germ Cell Tumors
   Int J Gynecol Pathol, 42 (6), 613-619
   DOI 10.1097/PGP.0000000000000947, PubMed 37186896
10. Dos Santos MV, Holth A, Bischof K, Davidson B (2023)
    Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
    Clin Exp Metastasis, 41 (1), 69-76
    DOI 10.1007/s10585-023-10251-5, PubMed 38141113
11. Dos Santos MV, Holth A, Lindemann K, Staff AC, Davidson B (2023)
    Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
    Gynecol Oncol, 176, 76-81
    DOI 10.1016/j.ygyno.2023.07.004, PubMed 37478615
12. Fortner RT, Trewin-Nybråten CB, Paulsen T, Langseth H (2023)
    Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway
    Int J Cancer, 153 (5), 969-978
    DOI 10.1002/ijc.34576, PubMed 37226635
13. Fotopoulou C, Eriksson AG, Yagel I, Chang SJ, Lim MC (2023)
    Surgery for Recurrent Epithelial Ovarian Cancer
    Curr Oncol Rep, 26 (1), 46-54
    DOI 10.1007/s11912-023-01480-8, PubMed 38091202
14. Grisham RN, Vergote I, Banerjee S, Drill E, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Cibula D, Moore KN, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Kristensen G et al. (2023)
    Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
    Clin Cancer Res, 29 (20), 4068-4075
    DOI 10.1158/1078-0432.CCR-23-0621, PubMed 37581616
15. Joneborg U, Bergamini A, Wallin E, Mangili G, Solheim O, Marquina G, Casado A, Rokkones E, Coulter J, Lok CAR, van Trommel N, Amant F, Bolze PA, Sehouli J, Han S, Kridelka F, Goffin F, Pautier P, Ray-Coquard I, Seckl M (2023)
    European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors
    Int J Gynecol Cancer, 33 (10), 1621-1626
    DOI 10.1136/ijgc-2023-004599, PubMed 37783481
16. Kacperczyk-Bartnik J, Bilir E, Nasser S, Strojna A, Eriksson AGZ (2023)
    Is it possible to block cancer? The example of #VaginalCancer on Instagram
    Int J Gynecol Cancer, 33 (9), 1488-1489
    DOI 10.1136/ijgc-2023-004844, PubMed 37591610
17. Karamouza E, Glasspool RM, Kelly C, Lewsley LA, Carty K, Kristensen GB, Ethier JL, Kagimura T, Yanaihara N, Cecere SC, You B, Boere IA, Pujade-Lauraine E, Ray-Coquard I, Proust-Lima C, Paoletti X (2023)
    CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
    Cancers (Basel), 15 (6)
    DOI 10.3390/cancers15061823, PubMed 36980708
18. Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S (2023)
    Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
    Clin Cancer Res, 29 (9), 1698-1707
    DOI 10.1158/1078-0432.CCR-22-2032, PubMed 36595569
19. Lindemann K, Heimisdottir Danbolt S, Ramberg L, Eyjólfsdóttir B, Wang YY, Heli-Haugestøl AG, Walcott SL, Mjåland O, Navestad GA, Hermanrud S, Juul-Hansen KE, Bragstad LK, Opheim R, Kleppe A, Kongsgaard U (2023)
    Patient-reported nausea after implementation of an enhanced recovery after surgery protocol for gynae-oncology patients
    Int J Gynecol Cancer, 33 (8), 1287-1294
    DOI 10.1136/ijgc-2023-004356, PubMed 37451689
20. Lindemann K, Kleppe A, Eyjólfsdóttir B, Heimisdottir Danbolt S, Wang YY, Heli-Haugestøl AG, Walcott SL, Mjåland O, Navestad GA, Hermanrud S, Juul-Hansen KE, Kongsgaard U (2023)
    Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer
    Int J Gynecol Cancer, 33 (8), 1279-1286
    DOI 10.1136/ijgc-2023-004355, PubMed 37451690
21. Lundberg FE, Stensheim H, Ullenhag GJ, Sahlgren HM, Lindemann K, Fredriksson I, Johansson ALV (2023)
    Risk factors for the increasing incidence of pregnancy-associated cancer in Sweden - a population-based study
    Acta Obstet Gynecol Scand, 103 (4), 669-683
    DOI 10.1111/aogs.14677, PubMed 37694965
22. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ et al. (2023)
    Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
    N Engl J Med, 388 (23), 2145-2158
    DOI 10.1056/NEJMoa2216334, PubMed 36972026
23. Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C et al. (2023)
    Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
    Lancet, 403 (10421), 31-43
    DOI 10.1016/S0140-6736(23)02405-4, PubMed 38048793
24. Opheim LØ, Engeskaug I, Bjerre Trent PK, Thorsen L, Staff AC, Nordskar NJ, Utne I, Hagen M, Eriksson AGZ (2023)
    Associations between modifiable lifestyle factors and health-related quality of life among endometrial carcinoma survivors - A cross-sectional study
    Gynecol Oncol, 179, 52-62
    DOI 10.1016/j.ygyno.2023.10.012, PubMed 37924595
25. Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A, OReO/ENGOT-ov38 investigators (2023)
    Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
    Ann Oncol, 34 (12), 1152-1164
    DOI 10.1016/j.annonc.2023.09.3110, PubMed 37797734
26. Skaali T, Blomhoff R, Lindemann K, Smeland S, Bruheim K, Seland M, Thorsen L (2023)
    Self-reported distress and problems after treatment for gynecological cancer - Correlation between a short screening tool and longer measures of anxiety/depression and health-related quality of life
    Acta Obstet Gynecol Scand, 103 (2), 387-395
    DOI 10.1111/aogs.14709, PubMed 37991142
27. Valstad H, Eyjolfsdottir B, Wang Y, Kristensen GB, Skeie-Jensen T, Lindemann K (2023)
    Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective analysis
    Eur J Surg Oncol, 49 (9), 106958
    DOI 10.1016/j.ejso.2023.06.010, PubMed 37349160
28. Vilming B, Fallås Dahl J, Bentzen AG, Ingebrigtsen VA, Berge Nilsen E, Vistad I, Dørum A, Solheim O, Bjørge L, Zucknick M, Aune G, Lindemann K (2023)
    Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer
    Int J Gynecol Cancer, 33 (12), 1898-1905
    DOI 10.1136/ijgc-2023-004484, PubMed 38000795

Publications 2022

1. Baranovicova E, Racay P, Zubor P, Smolar M, Kudelova E, Halasova E, Dvorska D, Dankova Z (2022)
   Circulating metabolites in the early stage of breast cancer were not related to cancer stage or subtypes but associated with ki67 level. Promising statistical discrimination from controls
   Mol Cell Probes, 66, 101862
   DOI 10.1016/j.mcp.2022.101862, PubMed 36162596
2. Brunetti M, Panagopoulos I, Vitelli V, Andersen K, Hveem TS, Davidson B, Eriksson AGZ, Trent PKB, Heim S, Micci F (2022)
   Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile
   Cancers (Basel), 14 (14)
   DOI 10.3390/cancers14143536, PubMed 35884597
3. Davidson B, Elstrand MB (2022)
   Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions
   Cytopathology, 33 (4), 479-492
   DOI 10.1111/cyt.13126, PubMed 35398934
4. Daviu C, Blaakaer J, Eriksson AGZ, Herrstedt J, Vandborg MP, Rasmussen AMO, Fuglsang K (2022)
   Nonepithelial ovarian cancer - the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO)
   Acta Oncol, 61 (8), 939-945
   DOI 10.1080/0284186X.2022.2088249, PubMed 35762031
5. Gatius S, Velasco A, Varela M, Cuatrecasas M, Jares P, Setaffy L, Bonhomme B, Santon A, Lindemann K, Croce S, Davidson B, Lax S, Palacios J, Matias-Guiu X (2022)
   Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
   Virchows Arch, 480 (5), 1031-1039
   DOI 10.1007/s00428-022-03291-x, PubMed 35124717
6. Kurnit KC, Nobre SP, Fellman BM, Iglesias DA, Lindemann K, Jhingran A, Eriksson AGZ, Ataseven B, Glaser GE, Mueller JJ, Westin SN, Soliman PT (2022)
   Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study
   Gynecol Oncol, 167 (3), 452-457
   DOI 10.1016/j.ygyno.2022.09.025, PubMed 36243601
7. Madland K, Bjorge L, Småstuen MC, Dørum A, Vistad I (2022)
   Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?
   Int J Gynecol Cancer, 32 (8), 1025-1031
   DOI 10.1136/ijgc-2022-003361, PubMed 35680138
8. Marth C, Abreu MH, Andersen KK, Aro KM, de Lurdes Batarda M, Boll D, Ekmann-Gade AW, Haltia UM, Hansen J, Haug AJ, Høgdall C, Korach J, Lassus H, Lindemann K, Van Nieuwenhuysen E, Ottevanger PB, Polterauer S, Schnack TH (2022)
   Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
   Cancer, 128 (16), 3080-3089
   DOI 10.1002/cncr.34350, PubMed 35714310
9. Nilsen A, Hillestad T, Skingen VE, Aarnes EK, Fjeldbo CS, Hompland T, Evensen TS, Stokke T, Kristensen GB, Grallert B, Lyng H (2022)
   miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
   Mol Oncol, 16 (6), 1402-1419
   DOI 10.1002/1878-0261.13184, PubMed 35064630
10. O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A (2022)
    Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
    Gynecol Oncol, 166 (1), 36-43
    DOI 10.1016/j.ygyno.2022.04.012, PubMed 35550709
11. Paulsen T, Liland H, Myklebust TÅ, Lindemann K (2022)
    Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study
    Int J Gynecol Cancer, 32 (2), 181-188
    DOI 10.1136/ijgc-2021-002898, PubMed 34987096
12. Pfisterer J, Joly F, Kristensen G, Rau J, Mahner S, Pautier P, El-Balat A, Kurtz JE, Canzler U, Sehouli J, Heubner ML, Hartkopf AD, Baumann K, Hasenburg A, Hanker LC, Belau A, Schmalfeldt B, Denschlag D, Park-Simon TW, Selle F, Jackisch C, Burges A, Lück HJ, Emons G, Meier W et al. (2022)
    Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
    J Clin Oncol, 41 (4), 893-902
    DOI 10.1200/JCO.22.01010, PubMed 36332161
13. Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E (2022)
    Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
    Gynecol Oncol, 164 (3), 498-504
    DOI 10.1016/j.ygyno.2021.12.025, PubMed 35063276
14. Siegenthaler F, Lindemann K, Epstein E, Rau TT, Nastic D, Ghaderi M, Rydberg F, Mueller MD, Carlson J, Imboden S (2022)
    Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification
    Gynecol Oncol, 165 (2), 230-238
    DOI 10.1016/j.ygyno.2022.02.024, PubMed 35277281
15. Skipar K, Hompland T, Lund KV, Løndalen A, Malinen E, Kristensen GB, Lindemann K, Nakken ES, Bruheim K, Lyng H (2022)
    Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer
    Radiother Oncol, 176, 17-24
    DOI 10.1016/j.radonc.2022.09.002, PubMed 36113778
16. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
    A national precision cancer medicine implementation initiative for Norway
    Nat Med, 28 (5), 885-887
    DOI 10.1038/s41591-022-01777-4, PubMed 35513529
17. Utne I, Stokke K, Ritchie C, Løyland B, Grov EK, Rasmussen HL, Lindemann K, Paul SM, Torstveit AH, Miaskowski C (2022)
    Changes in Subjective Measures of Cognitive Function in Older Adults From the Initiation Through 12 Months After the Receipt of Chemotherapy
    Cancer Nurs, 46 (6), E365-E374
    DOI 10.1097/NCC.0000000000001140, PubMed 35781267

Publications 2021

1. Areklett EW, Fagereng E, Bruheim K, Andersson S, Lindemann K (2021)
   Self-reported cognitive impairment in cervical cancer survivors: A cross-sectional study
   Psychooncology, 31 (2), 298-305
   DOI 10.1002/pon.5818, PubMed 34516040
2. Bhandoria GP, Nair N, Jones SEF, Eriksson AG, Hsu HC, Noll F, Ahmed W, International Gynecological Cancer Society (2021)
   International Gynaecological Cancer Society (IGCS) 2020 Annual Global Meeting: Twitter activity analysis
   Int J Gynecol Cancer, 31 (11), 1453-1458
   DOI 10.1136/ijgc-2021-002781, PubMed 34489352
3. Davidson B, Kleinberg L, Børresen IM, Slettevoll F, Fangberget A, Hindosh D, Zahl Eriksson AG, Bjerkehagen B (2021)
   Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis
   Virchows Arch, 479 (2), 419-424
   DOI 10.1007/s00428-021-03057-x, PubMed 33595736
4. Eriksson AGZ, Davidson B, Bjerre Trent P, Eyjólfsdóttir B, Dahl GF, Wang Y, Staff AC (2021)
   Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
   J Clin Med, 10 (14)
   DOI 10.3390/jcm10143094, PubMed 34300260
5. Eriksson AGZ, Mueller JJ (2021)
   Advances in management of nonendometrioid endometrial carcinoma, with an emphasis on the sentinel lymph node technique
   Curr Opin Oncol, 33 (5), 457-463
   DOI 10.1097/CCO.0000000000000777, PubMed 34264897
6. Gansmo LB, Sofiyeva N, Bjørnslett M, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
   Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
   Sci Rep, 11 (1), 23463
   DOI 10.1038/s41598-021-02820-z, PubMed 34873230
7. Helwa R, Gansmo LB, Bjørnslett M, Halle MK, Werner HMJ, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2021)
   Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
   Biomarkers, 26 (4), 302-308
   DOI 10.1080/1354750X.2021.1891291, PubMed 33645339
8. Kargo AS, Jensen PT, Lindemann K, Hjollund NHI, Lund B, Haee M, Möller S, Hansen DG, Dahl Steffensen K (2021)
   The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness
   Acta Oncol, 60 (4), 434-443
   DOI 10.1080/0284186X.2021.1891281, PubMed 33651647
9. Kargo AS, Jensen PT, Lindemann K, Hjøllund NH, Liposits GI, Raaschou-Jensen N, Knudsen BM, Möller S, Hansen DG, Steffensen KD (2021)
   Association of patient-reported outcomes and ovarian cancer recurrence
   Int J Gynecol Cancer, 31 (9), 1248-1259
   DOI 10.1136/ijgc-2021-002550, PubMed 34489355
10. Kasius JC, Pijnenborg JMA, Lindemann K, Forsse D, van Zwol J, Kristensen GB, Krakstad C, Werner HMJ, Amant F (2021)
    Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
    Cancers (Basel), 13 (22)
    DOI 10.3390/cancers13225848, PubMed 34831000
11. Kolkova Z, Holubekova V, Grendar M, Nachajova M, Zubor P, Pribulova T, Loderer D, Zigo I, Biringer K, Hornakova A (2021)
    Association of Circulating miRNA Expression with Preeclampsia, Its Onset, and Severity
    Diagnostics (Basel), 11 (3)
    DOI 10.3390/diagnostics11030476, PubMed 33800458
12. Lindemann K (2021)
    Medical treatment of primary and recurrent cervical cancer
    Int. J. Gynecol. Cancer, 31 1, 20
13. Lindemann K (2021)
    Medical treatment of primary and recurrent cervical cancer
    Int. J. Gynecol. Cancer, 31 2, 18
14. Lindemann K, Smogeli E, Småstuen MC, Bruheim K, Trovik J, Nordberg T, Kristensen GB, Werner HMJ, Nakken E (2021)
    Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer
    Cancers (Basel), 13 (6)
    DOI 10.3390/cancers13061367, PubMed 33803531
15. Oonk MHM, Slomovitz B, Baldwin PJW, van Doorn HC, van der Velden J, de Hullu JA, Gaarenstroom KN, Slangen BFM, Vergote I, Brännström M, van Dorst EBL, van Driel WJ, Hermans RH, Nunns D, Widschwendter M, Nugent D, Holland CM, Sharma A, DiSilvestro PA, Mannel R, Boll D, Cibula D, Covens A, Provencher D, Runnebaum IB et al. (2021)
    Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
    J Clin Oncol, 39 (32), 3623-3632
    DOI 10.1200/JCO.21.00006, PubMed 34432481
16. Seland M, Skrede K, Lindemann K, Skaali T, Blomhoff R, Bruheim K, Wisløff T, Thorsen L (2021)
    Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer
    Acta Obstet Gynecol Scand, 101 (3), 313-322
    DOI 10.1111/aogs.14310, PubMed 34964982
17. Seppälä TT, Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W et al. (2021)
    Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report
    Eur J Cancer, 148, 124-133
    DOI 10.1016/j.ejca.2021.02.022, PubMed 33743481
18. Sert BM, Kristensen GB, Kleppe A, Dørum A (2021)
    Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
    Gynecol Oncol, 162 (2), 284-291
    DOI 10.1016/j.ygyno.2021.05.028, PubMed 34083029
19. Skorstad M, de Rooij BH, Jeppesen MM, Bergholdt SH, Ezendam NPM, Bohlin T, Jensen PT, Lindemann K, van de Poll L, Vistad I (2021)
    Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study
    Int J Gynecol Cancer, 31 (8), 1106-1115
    DOI 10.1136/ijgc-2020-002377, PubMed 33858949
20. Utne I, Løyland B, Grov EK, Rasmussen HL, Torstveit AH, Paul SM, Ritchie C, Lindemann K, Vistad I, Rodríguez-Aranda C, Miaskowski C (2021)
    Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy
    Nurs Open, 9 (2), 1040-1051
    DOI 10.1002/nop2.1141, PubMed 34878233
21. van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Forsse D, Witteveen PO, Galaal K, van Ginkel A, Bignotti E, Weinberger V, Sweegers S, Kroep JR, Cabrera S, Snijders MPLM, Inda MA, Eriksson AGZ, European Network for Individualized Treatment in Endometrial Cancer, Krakstad C, Romano A et al. (2021)
    Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
    Am J Obstet Gynecol, 225 (4), 407.e1-407.e16
    DOI 10.1016/j.ajog.2021.05.007, PubMed 34019887
22. Vistad I, Skorstad M, Demmelmaier I, Småstuen MC, Lindemann K, Wisløff T, van de Poll-Franse LV, Berntsen S (2021)
    Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking
    BMJ Open, 11 (7), e050930
    DOI 10.1136/bmjopen-2021-050930, PubMed 34253678

Publications 2020

1. Fjeldbo CS, Hompland T, Hillestad T, Aarnes EK, Günther CC, Kristensen GB, Malinen E, Lyng H (2020)
   Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
   EBioMedicine, 57, 102841
   DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139
2. Harter P, Pautier P, Van Nieuwenhuysen E, Reuss A, Redondo A, Lindemann K, Kurzeder C, Petru E, Heitz F, Sehouli J, Degregorio N, Wimberger P, Burges A, Cron N, Ledermann J, Lorusso D, Paoletti X, Marme F (2020)
   Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
   Int J Gynecol Cancer, 30 (12), 1997-2001
   DOI 10.1136/ijgc-2020-001572, PubMed 32606097
3. Hillestad T, Hompland T, Fjeldbo CS, Skingen VE, Salberg UB, Aarnes EK, Nilsen A, Lund KV, Evensen TS, Kristensen GB, Stokke T, Lyng H (2020)
   MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
   Cancer Res, 80 (18), 3993-4003
   DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004
4. Holubekova V, Kolkova Z, Grendar M, Brany D, Dvorska D, Stastny I, Jagelkova M, Zelinova K, Samec M, Liskova A, Laucekova Z, Kudela E, Bobrovska M, Kalman M, Zubor P, Dankova Z (2020)
   Pathway Analysis of Selected Circulating miRNAs in Plasma of Breast Cancer Patients: A Preliminary Study
   Int J Mol Sci, 21 (19)
   DOI 10.3390/ijms21197288, PubMed 33023154
5. Kargo AS, Coulter A, Lindemann K, Jensen PT, Hjøllund NH, Mosgaard BJ, Steffensen KD (2020)
   Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol
   Int J Gynecol Cancer, 30 (9), 1444-1449
   DOI 10.1136/ijgc-2020-001528, PubMed 32586892
6. Kleppe A, Albregtsen F, Trovik J, Kristensen GB, Danielsen HE (2020)
   Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas
   Cancers (Basel), 12 (12)
   DOI 10.3390/cancers12123838, PubMed 33352679
7. Koklesova L, Liskova A, Samec M, Qaradakhi T, Zulli A, Smejkal K, Kajo K, Jakubikova J, Behzadi P, Pec M, Zubor P, Biringer K, Kwon TK, Büsselberg D, Sarria GR, Giordano FA, Golubnitschaja O, Kubatka P (2020)
   Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine
   EPMA J, 11 (2), 261-287
   DOI 10.1007/s13167-020-00210-5, PubMed 32547652
8. Lanner M, Nikolova T, Gutic B, Nikolova N, Pletnev A, Selcuk I, Vlachos DE, Razumova Z, Bizzarri N, Theofanakis C, Lepka P, Kahramanoglu I, Han S, Nasser S, Molnar S, Hudry D, Montero-Macías R, de Lange N, Macuks R, Hasanov MF, Karimbayli R, Gagua I, Andrade C, Pardal C, Dotlic J et al. (2020)
   Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists
   Int J Gynecol Cancer, 31 (4), 575-584
   DOI 10.1136/ijgc-2020-002176, PubMed 33361458
9. Lindemann K (2020)
   Systematic treatment of primary and recurrent cervical cancer
   Int. J. Gynecol. Cancer, 30 1, 15
10. Lindemann K, Martinsson L, Kaasa S, Lindquist D (2020)
    Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
    Acta Oncol, 59 (6), 636-643
    DOI 10.1080/0284186X.2020.1744717, PubMed 32238040
11. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2020)
    DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
    Radiat Oncol, 15 (1), 79
    DOI 10.1186/s13014-020-01526-2, PubMed 32293487
12. Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA (2020)
    Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
    Gynecol Oncol, 159 (2), 442-448
    DOI 10.1016/j.ygyno.2020.09.006, PubMed 32981695
13. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C et al. (2020)
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
    J Clin Oncol, 38 (32), 3753-3762
    DOI 10.1200/JCO.20.01164, PubMed 32822286
14. Norell CH, Butler J, Farrell R, Altman A, Bentley J, Cabasag CJ, Cohen PA, Fegan S, Fung-Kee-Fung M, Gourley C, Hacker NF, Hanna L, Høgdall CK, Kristensen G, Kwon J, McNally O, Nelson G, Nordin A, O'Donnell D, Schnack T, Sykes PH, Zotow E, Harrison S (2020)
    Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care
    Int J Gynecol Cancer, 30 (11), 1748-1756
    DOI 10.1136/ijgc-2020-001403, PubMed 32784203
15. Paoletti X, Lewsley LA, Daniele G, Cook A, Yanaihara N, Tinker A, Kristensen G, Ottevanger PB, Aravantinos G, Miller A, Boere IA, Fruscio R, Reyners AKL, Pujade-Lauraine E, Harkin A, Pignata S, Kagimura T, Welch S, Paul J, Karamouza E, Glasspool RM, Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee (2020)
    Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
    JAMA Netw Open, 3 (1), e1918939
    DOI 10.1001/jamanetworkopen.2019.18939, PubMed 31922558
16. Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez Martin A, Jhingran A, Pareja R (2020)
    COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
    Int J Gynecol Cancer, 30 (5), 561-563
    DOI 10.1136/ijgc-2020-001419, PubMed 32221023
17. Ramirez PT, Pareja R, Eriksson AGZ, Frumovitz M (2020)
    International Gynecologic Cancer Society 2019 meeting summary
    Int J Gynecol Cancer, 30 (2), 167-173
    DOI 10.1136/ijgc-2019-001146, PubMed 32029483
18. Rolfsen ALD, Dahl AA, Pripp AH, Dørum A (2020)
    Base rate of ovarian cancer on algorithms in patients with a pelvic mass
    Int J Gynecol Cancer, 30 (11), 1775-1779
    DOI 10.1136/ijgc-2020-001416, PubMed 32699016
19. Salminen L, Nadeem N, Rolfsen AL, Dørum A, Laajala TD, Grènman S, Hietanen S, Heinosalo T, Perheentupa A, Poutanen M, Bolstad N, Carpén O, Lamminmäki U, Pettersson K, Gidwani K, Hynninen J, Huhtinen K (2020)
    Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
    J Appl Lab Med, 5 (2), 263-272
    DOI 10.1093/jalm/jfz012, PubMed 32445385
20. Samec M, Liskova A, Koklesova L, Samuel SM, Murin R, Zubor P, Bujnak J, Kwon TK, Büsselberg D, Prosecky R, Caprnda M, Rodrigo L, Ciccocioppo R, Kruzliak P, Kubatka P (2020)
    The role of plant-derived natural substances as immunomodulatory agents in carcinogenesis
    J Cancer Res Clin Oncol, 146 (12), 3137-3154
    DOI 10.1007/s00432-020-03424-2, PubMed 33063131
21. Samec M, Liskova A, Koklesova L, Samuel SM, Zhai K, Buhrmann C, Varghese E, Abotaleb M, Qaradakhi T, Zulli A, Kello M, Mojzis J, Zubor P, Kwon TK, Shakibaei M, Büsselberg D, Sarria GR, Golubnitschaja O, Kubatka P (2020)
    Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
    EPMA J, 11 (3), 377-398
    DOI 10.1007/s13167-020-00217-y, PubMed 32843908
22. Sharma A, Davidson B, Skeie-Jensen T, Wang Y (2020)
    Fifteen Years’ Experience with Vulvar Verrucous Carcinoma at a Single Norwegian Academic Cancer Center
    Journal of Gynecology and Women Healthcare, 2 (2), 1-4
    PublikaID 489
23. Stastny I, Zubor P, Kajo K, Kubatka P, Golubnitschaja O, Dankova Z (2020)
    Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer
    Clin Breast Cancer, 20 (6), e711-e722
    DOI 10.1016/j.clbc.2020.05.009, PubMed 32792225
24. Vistad I, Lindemann K, Bentzen AG, Dahl AA, Steen R, Kiserud C (2020)
    Preferences for follow up in long-term survivors after cervical cancer
    Acta Obstet Gynecol Scand, 99 (9), 1253-1259
    DOI 10.1111/aogs.13855, PubMed 32232835
25. Zubor P, Dankova Z, Kolkova Z, Holubekova V, Brany D, Mersakova S, Samec M, Liskova A, Koklesova L, Kubatka P, Bujnak J, Kajo K, Mlyncek M, Giordano FA, Golubnitschaja O (2020)
    Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare
    Cancers (Basel), 12 (5)
    DOI 10.3390/cancers12051292, PubMed 32443784
26. Zubor P, Wang Y, Liskova A, Samec M, Koklesova L, Dankova Z, Dørum A, Kajo K, Dvorska D, Lucansky V, Malicherova B, Kasubova I, Bujnak J, Mlyncek M, Dussan CA, Kubatka P, Büsselberg D, Golubnitschaja O (2020)
    Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology
    Int J Mol Sci, 21 (21)
    DOI 10.3390/ijms21217988, PubMed 33121141

Publications 2019

1. Binzer-Panchal A, Hardell E, Viklund B, Ghaderi M, Bosse T, Nucci MR, Lee CH, Hollfelder N, Corcoran P, Gonzalez-Molina J, Moyano-Galceran L, Bell DA, Schoolmeester JK, Måsbäck A, Kristensen GB, Davidson B, Lehti K, Isaksson A, Carlson JW (2019)
   Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
   Clin Cancer Res, 25 (7), 2155-2165
   DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134
2. Eriksson AG, Fallaas Dahl G, Nesbakken AJ, Lund KV, Amant F (2019)
   Endometrial cancer during pregnancy: management strategies
   Int J Gynecol Cancer, 29 (7), 1221-1224
   DOI 10.1136/ijgc-2019-000756, PubMed 31434687
3. Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA (2019)
   Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
   Gynecol Oncol, 152 (3), 560-567
   DOI 10.1016/j.ygyno.2018.12.009, PubMed 30638768
4. Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H (2019)
   Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
   Neoplasia, 21 (4), 353-362
   DOI 10.1016/j.neo.2019.01.002, PubMed 30856376
5. Lindemann K, Zalewski K, Halaska MJ (2019)
   Summary of landmark papers published between August 2018 and May 2019
   Int. J. Gynecol. Cancer, 29 1, 1-5
   DOI 10.1136/ijgc-2019-000738
6. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2019)
   Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model
   Acta Oncol, 58 (6), 828-837
   DOI 10.1080/0284186X.2019.1580386, PubMed 30810443
7. Nilsen A, Jonsson M, Aarnes EK, Kristensen GB, Lyng H (2019)
   Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
   Transl Oncol, 12 (3), 576-584
   DOI 10.1016/j.tranon.2018.12.010, PubMed 30660934
8. Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K (2019)
   Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
   Int J Gynecol Cancer, 29 (1), 181-187
   DOI 10.1136/ijgc-2018-000021, PubMed 30640702
9. Roncolato F, Lindemann K, Willson ML, Martyn J, Mileshkin L (2019)
   PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
   Cochrane Database Syst Rev, 10 (10), CD012160
   DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998

Publications 2018

1. González Martín A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Bertrand MA, Beale P, Cervantes A, Kent E, Kaplan RS, Parmar MKB, Scotto N, Perren TJ, ICON7 investigators (2018)
   Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
   Gynecol Oncol, 152 (1), 53-60
   DOI 10.1016/j.ygyno.2018.08.036, PubMed 30449719
2. Kleppe A, Albregtsen F, Vlatkovic L, Pradhan M, Nielsen B, Hveem TS, Askautrud HA, Kristensen GB, Nesbakken A, Trovik J, Wæhre H, Tomlinson I, Shepherd NA, Novelli M, Kerr DJ, Danielsen HE (2018)
   Chromatin organisation and cancer prognosis: a pan-cancer study
   Lancet Oncol, 19 (3), 356-369
   DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700
3. Lindemann K (2018)
   Medical treatment of primary and recurrent cervical cancer
   Int. J. Gynecol. Cancer, 28 4, 29
4. Lindemann K, Beale PJ, Rossi E, Goh JC, Vaughan MM, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin E, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D, For ANZGOG and HCRN Collaborative Groups (2018)
   Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
   Cancer Chemother Pharmacol, 83 (1), 97-105
   DOI 10.1007/s00280-018-3706-5, PubMed 30368585
5. Lindemann K, Gao B, Mapagu C, Fereday S, Emmanuel C, Alsop K, Traficante N, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DDL, deFazio A (2018)
   Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
   Gynecol Oncol, 150 (2), 239-246
   DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697
6. Lindemann K, Zalewski K, Halaska MJ, Lindquist D (2018)
   PREFACE
   Int. J. Gynecol. Cancer, 28 4, 2
7. Lønning PE, Berge EO, Bjørnslett M, Minsaas L, Chrisanthar R, Høberg-Vetti H, Dulary C, Busato F, Bjørneklett S, Eriksen C, Kopperud R, Axcrona U, Davidson B, Bjørge L, Evans G, Howell A, Salvesen HB, Janszky I, Hveem K, Romundstad PR, Vatten LJ, Tost J, Dørum A, Knappskog S (2018)
   White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
   Ann Intern Med, 168 (5), 326-334
   DOI 10.7326/M17-0101, PubMed 29335712
8. Nielsen B, Kleppe A, Hveem TS, Pradhan M, Syvertsen RA, Nesheim JA, Kristensen GB, Trovik J, Kerr DJ, Albregtsen F, Danielsen HE (2018)
   Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
   J Natl Cancer Inst, 110 (12), 1400-1408
   DOI 10.1093/jnci/djy063, PubMed 29684152
9. Noer MC, Leandersson P, Paulsen T, Rosthøj S, Antonsen SL, Borgfeldt C, Høgdall C (2018)
   Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
   Acta Oncol, 57 (8), 1100-1108
   DOI 10.1080/0284186X.2018.1440085, PubMed 29451070
10. Simonsen TG, Lund KV, Hompland T, Kristensen GB, Rofstad EK (2018)
    DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
    Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
    DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790
11. Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K (2018)
    Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
    Int J Gynecol Cancer, 28 (9), 1789-1795
    DOI 10.1097/IGC.0000000000001356, PubMed 30365455
12. Solheim O, Skalleberg J, Warncke T, Ørstavik K, Tropé C, Fosså SD (2018)
    Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
    Acta Obstet Gynecol Scand, 98 (2), 240-249
    DOI 10.1111/aogs.13477, PubMed 30289161
13. Szczesny W, Langseth H, Myklebust TÅ, Kaern J, Tropé C, Paulsen T (2018)
    Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
    Acta Obstet Gynecol Scand, 97 (8), 956-965
    DOI 10.1111/aogs.13361, PubMed 29790149

Publications 2017

1. Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
   MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
   Oncotarget, 8 (37), 61800-61809
   DOI 10.18632/oncotarget.18694, PubMed 28977905
2. Davidson B, Hellesylt E, Holth A, Danielsen HE, Skeie-Jensen T, Katz B (2017)
   Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
   Virchows Arch, 471 (3), 355-362
   DOI 10.1007/s00428-017-2172-5, PubMed 28643014
3. Eriksson AG, Beavis A, Soslow RA, Zhou Q, Abu-Rustum NR, Gardner GJ, Zivanovic O, Long Roche K, Sonoda Y, Leitao MM, Jewell EL (2017)
   A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer
   Int J Gynecol Cancer, 27 (4), 743-747
   DOI 10.1097/IGC.0000000000000959, PubMed 28375931
4. Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Romundstad P, Hveem K, Vatten L, Dørum A, Lønning PE, Knappskog S (2017)
   MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
   BMC Cancer, 17 (1), 97
   DOI 10.1186/s12885-017-3094-y, PubMed 28158999
5. Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R (2017)
   TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
   Virchows Arch, 470 (6), 665-678
   DOI 10.1007/s00428-017-2127-x, PubMed 28432432
6. Hardell E, Josefson S, Ghaderi M, Skeie-Jensen T, Westbom-Fremer S, Cheek EH, Bell D, Selling J, Schoolmeester JK, Måsbäck A, Davidson B, Carlson JW (2017)
   Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
   Am J Surg Pathol, 41 (9), 1231-1237
   DOI 10.1097/PAS.0000000000000894, PubMed 28622181
7. Johansen N, Liavaag AH, Iversen OE, Dørum A, Braaten T, Michelsen TM (2017)
   Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
   Acta Obstet Gynecol Scand, 96 (5), 547-555
   DOI 10.1111/aogs.13120, PubMed 28236297
8. Landskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett M, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen HB, Taskén K (2017)
   C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
   PLoS One, 12 (7), e0182030
   DOI 10.1371/journal.pone.0182030, PubMed 28759630
9. Lindemann K, Gibbs E, Åvall-Lundqvist E, dePont Christensen R, Woie K, Kalling M, Auranen A, Grenman S, Hoegberg T, Rosenberg P, Skeie-Jensen T, Hjerpe E, Dørum A, Gebski V, Kristensen G (2017)
   Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
   Br J Cancer, 116 (4), 455-463
   DOI 10.1038/bjc.2016.435, PubMed 28118323
10. Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A (2017)
    Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
    Int J Gynecol Cancer, 27 (6), 1274-1282
    DOI 10.1097/IGC.0000000000000981, PubMed 28498237
11. Lindemann K, Kok PS, Stockler M, Sykes P, Brand A (2017)
    Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
    Int J Gynecol Cancer, 27 (5), 1046-1050
    DOI 10.1097/IGC.0000000000000982, PubMed 28525497
12. Lund KV, Simonsen TG, Kristensen GB, Rofstad EK (2017)
    Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
    Acta Oncol, 56 (5), 675-681
    DOI 10.1080/0284186X.2017.1294762, PubMed 28447564
13. Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I (2017)
    Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
    Gynecol Oncol, 145 (3), 543-548
    DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187
14. Minig L, Heitz F, Cibula D, Bakkum-Gamez JN, Germanova A, Dowdy SC, Kalogera E, Zapardiel I, Lindemann K, Harter P, Scambia G, Petrillo M, Zorrero C, Zanagnolo V, Rebollo JMC, du Bois A, Fotopoulou C (2017)
    Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
    Ann Surg Oncol, 24 (9), 2720-2726
    DOI 10.1245/s10434-017-5919-y, PubMed 28608122
15. Ray-Coquard I, Trama A, Seckl MJ, Fotopoulou C, Pautier P, Pignata S, Kristensen G, Mangili G, Falconer H, Massuger L, Sehouli J, Pujade-Lauraine E, Lorusso D, Amant F, Rokkones E, Vergote I, Ledermann JA, RARECARENet Working Group (2017)
    Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
    Eur J Surg Oncol, 45 (1), 67-74
    DOI 10.1016/j.ejso.2017.09.025, PubMed 29108961
16. Skalleberg J, Solheim O, Fosså SD, Småstuen MC, Osnes T, Gundersen POM, Bunne M (2017)
    Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer
    Gynecol Oncol, 145 (1), 148-153
    DOI 10.1016/j.ygyno.2017.02.006, PubMed 28202195
17. Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B (2017)
    Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
    APMIS, 125 (9), 781-786
    DOI 10.1111/apm.12715, PubMed 28585395
18. Steen R, Dahl AA, Hess SL, Kiserud CE (2017)
    A study of chronic fatigue in Norwegian cervical cancer survivors
    Gynecol Oncol, 146 (3), 630-635
    DOI 10.1016/j.ygyno.2017.05.028, PubMed 28552254
19. Vistad I, Bjørge L, Solheim O, Fiane B, Sachse K, Tjugum J, Skrøppa S, Bentzen AG, Stokstad T, Iversen GA, Salvesen HB, Kristensen GB, Dørum A (2017)
    A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
    Acta Obstet Gynecol Scand, 96 (10), 1162-1169
    DOI 10.1111/aogs.13199, PubMed 28795770
20. Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
    The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
    Neuro Oncol, 19 (7), 976-985
    DOI 10.1093/neuonc/now272, PubMed 28040713
21. Wiedmann MKH, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2017)
    Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
    Acta Oncol, 56 (10), 1302-1309
    DOI 10.1080/0284186X.2017.1330554, PubMed 28548875
22. Zalewski K, Lindemann K, Halaska MJ, Zapardiel I, Laky R, Chereau E, Lindquist D, Polterauer S, Sukhin V, Dursun P (2017)
    A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
    Int J Gynecol Cancer, 27 (3), 620-626
    DOI 10.1097/IGC.0000000000000917, PubMed 28187096

Publications 2016

1. Bjørge T, Skare GB, Bjørge L, Tropé A, Lönnberg S (2016)
   Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia
   Obstet Gynecol, 128 (6), 1265-1273
   DOI 10.1097/AOG.0000000000001777, PubMed 27824756
2. Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM (2016)
   Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
   Am J Clin Pathol, 145 (4), 449-58
   DOI 10.1093/ajcp/aqw030, PubMed 27149024
3. Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016)
   Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
   Clin Cancer Res, 22 (16), 4067-76
   DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812
4. Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016)
   Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
   PLoS One, 11 (5), e0156259
   DOI 10.1371/journal.pone.0156259, PubMed 27244197
5. Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S (2016)
   The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
   Tumour Biol, 37 (8), 10697-702
   DOI 10.1007/s13277-016-4940-2, PubMed 26867771
6. Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A (2016)
   Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
   Gynecol Oncol, 142 (3), 458-64
   DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035
7. Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A (2016)
   Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
   Gynecol Oncol, 140 (3), 457-62
   DOI 10.1016/j.ygyno.2016.01.022, PubMed 26807488
8. Horwitz V, Davidson B, Stern D, Tropé CG, Tavor Re'em T, Reich R (2016)
   Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
   PLoS One, 11 (9), e0162502
   DOI 10.1371/journal.pone.0162502, PubMed 27622508
9. Lindemann K (2016)
   Medical treatment of primary or recurrent cervical cancer
   Int. J. Gynecol. Cancer, 26 1, 42-43
10. Lindemann K, Halaska MJ, Zalewski K (2016)
    Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
    Int. J. Gynecol. Cancer, 26 1, 5-8
11. Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E (2016)
    Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
    Ann Oncol, 27 (8), 1505-10
    DOI 10.1093/annonc/mdw238, PubMed 27407100
12. Lindemann K, Zalewski K, Halaska MJ, LiFE Team (2016)
    Preface
    Int. J. Gynecol. Cancer, 26 1, 2
13. Lindemann K, Zalewski K, Halaska MJ, Lindquist D, The LiFE Team (2016)
    Life - Literature for ENYGO
    Int. J. Gynecol. Cancer, 26 4, 2-73
14. Lönnberg S, Andreassen T, Engesæter B, Lilleng R, Kleven C, Skare A, Johansson K, Fredheim CS, Tropé A (2016)
    Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention
    BMJ Open, 6 (11), e013728
    DOI 10.1136/bmjopen-2016-013728, PubMed 28186949
15. Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K (2016)
    Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
    Oncologist, 21 (6), 745-54
    DOI 10.1634/theoncologist.2015-0239, PubMed 27009938
16. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J et al. (2016)
    Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    N Engl J Med, 375 (22), 2154-2164
    DOI 10.1056/NEJMoa1611310, PubMed 27717299
17. Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
    MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
    Hum Pathol, 54, 74-81
    DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471
18. Sert BM, Boggess JF, Ahmad S, Jackson AL, Stavitzski NM, Dahl AA, Holloway RW (2016)
    Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer
    Eur J Surg Oncol, 42 (4), 513-22
    DOI 10.1016/j.ejso.2015.12.014, PubMed 26843445
19. Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
    L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
    BMC Cancer, 16, 596
    DOI 10.1186/s12885-016-2631-4, PubMed 27488577
20. Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E, AURELIA Investigators (2016)
    Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
    Gynecol Oncol, 144 (1), 65-71
    DOI 10.1016/j.ygyno.2016.11.006, PubMed 27871723
21. Szczesny W, Vistad I, Kaern J, Nakling J, Tropé C, Paulsen T (2016)
    Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
    Eur J Gynaecol Oncol, 37 (3), 305-11
    DOI 10.12892/ejgo3007.2016, PubMed 27352555
22. Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ (2016)
    Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
    Oncotarget, 7 (11), 12267-85
    DOI 10.18632/oncotarget.7860, PubMed 26943585
23. Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E (2016)
    Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
    Ann Oncol, 27 (9), 1733-9
    DOI 10.1093/annonc/mdw236, PubMed 27287207
24. Zalewski K, Lindemann K, Halaska MJ (2016)
    Medical treatment of primary ovarian cancer
    Int. J. Gynecol. Cancer, 26 1, 9-11
25. Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC (2016)
    Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
    Br J Cancer, 115 (2), 228-35
    DOI 10.1038/bjc.2016.194, PubMed 27351218

Publications 2015

1. Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M (2015)
   Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
   PLoS One, 10 (12), e0143178
   DOI 10.1371/journal.pone.0143178, PubMed 26629914
2. Bjørnslett M, Dahl AA, Sørebø Ø, Dørum A (2015)
   Psychological distress related to BRCA testing in ovarian cancer patients
   Fam Cancer, 14 (4), 495-504
   DOI 10.1007/s10689-015-9811-2, PubMed 25980896
3. Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R (2015)
   HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
   Hum Pathol, 48, 95-101
   DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230
4. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO et al. (2015)
   Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
   Lancet Oncol, 17 (1), 78-89
   DOI 10.1016/S1470-2045(15)00366-6, PubMed 26590673
5. Katz B, Tropé CG, Reich R, Davidson B (2015)
   MicroRNAs in Ovarian Cancer
   Hum Pathol, 46 (9), 1245-56
   DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350
6. Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H (2015)
   Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
   Epigenetics, 10 (10), 970-80
   DOI 10.1080/15592294.2015.1085140, PubMed 26291246
7. Lindemann K, Cvancarova M, Eskild A (2015)
   Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
   Gynecol Oncol, 139 (3), 476-80
   DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365
8. Murbraech K, Solheim O, Aulie HM, Fossa SD, Aakhus S (2015)
   The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer
   ESC Heart Fail, 2 (3), 142-149
   DOI 10.1002/ehf2.12048, PubMed 28834675
9. Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B (2015)
   Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
   Gynecol Oncol, 139 (1), 30-9
   DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338
10. Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B (2015)
    CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
    Mol Cancer, 14, 44
    DOI 10.1186/s12943-015-0317-1, PubMed 25889687
11. Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ, ICON7 trial investigators (2015)
    Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
    Lancet Oncol, 16 (8), 928-36
    DOI 10.1016/S1470-2045(15)00086-8, PubMed 26115797
12. Sehouli J, Fotopoulou C, Erol E, Richter R, Reuss A, Mahner S, Lauraine EP, Kristensen G, Herrstedt J, du Bois A, Pfisterer J (2015)
    Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
    Eur J Cancer, 51 (7), 825-32
    DOI 10.1016/j.ejca.2015.01.008, PubMed 25771433
13. Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S et al. (2015)
    HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
    Genome Med, 7, 108
    DOI 10.1186/s13073-015-0233-4, PubMed 26497652
14. Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2015)
    Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
    Eur J Epidemiol, 31 (1), 95-8
    DOI 10.1007/s10654-015-0033-6, PubMed 25903163

Publications 2014

1. Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B (2014)
   Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma
   Int J Gynecol Cancer, 24 (9 Suppl 3), S67-72
   DOI 10.1097/IGC.0000000000000205, PubMed 25033257
2. Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RY, Tropé C, Nesland JM, Thiery JP (2014)
   The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
   Hum Pathol, 46 (1), 1-8
   DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994
3. Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
   BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
   Virchows Arch, 464 (6), 701-7
   DOI 10.1007/s00428-014-1577-7, PubMed 24756216
4. Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK (2014)
   VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
   Hum Pathol, 45 (7), 1520-8
   DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803
5. Davidson B, Tropé CG (2014)
   Ovarian cancer: diagnostic, biological and prognostic aspects
   Womens Health (Lond), 10 (5), 519-33
   DOI 10.2217/whe.14.37, PubMed 25335543
6. Davidson B, Tropé CG, Reich R (2014)
   The clinical and diagnostic role of microRNAs in ovarian carcinoma
   Gynecol Oncol, 133 (3), 640-6
   DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546
7. Davidson B, Trope CG, Reich R (2014)
   The role of the tumor stroma in ovarian cancer
   Front Oncol, 4, 104
   DOI 10.3389/fonc.2014.00104, PubMed 24860785
8. Hompland T, Lund KV, Ellingsen C, Kristensen GB, Rofstad EK (2014)
   Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
   Radiother Oncol, 113 (1), 132-8
   DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501
9. Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z (2014)
   CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
   PLoS One, 9 (11), e112209
   DOI 10.1371/journal.pone.0112209, PubMed 25380303
10. Lindemann K, Malander S, Christensen RD, Mirza MR, Kristensen GB, Aavall-Lundqvist E, Vergote I, Rosenberg P, Boman K, Nordstrøm B (2014)
    Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
    BMC Cancer, 14, 68
    DOI 10.1186/1471-2407-14-68, PubMed 24498853
11. Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S (2014)
    Genomic profile of ovarian carcinomas
    BMC Cancer, 14, 315
    DOI 10.1186/1471-2407-14-315, PubMed 24886194
12. Micci F, Panagopoulos I, Thorsen J, Davidson B, Tropé CG, Heim S (2014)
    Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
    PLoS Biol, 12 (2), e1001784
    DOI 10.1371/journal.pbio.1001784, PubMed 24504521
13. Nielsen B, Hveem TS, Kildal W, Abeler VM, Kristensen GB, Albregtsen F, Danielsen HE (2014)
    Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
    Cytometry A, 87 (4), 315-25
    DOI 10.1002/cyto.a.22601, PubMed 25483227
14. Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA (2014)
    Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
    Gynecol Oncol, 135 (1), 118-24
    DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290
15. Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F (2014)
    Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
    Genes Chromosomes Cancer, 53 (7), 558-67
    DOI 10.1002/gcc.22166, PubMed 24634323
16. Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD (2014)
    Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
    Eur J Cancer, 50 (11), 1942-50
    DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045
17. Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD (2014)
    Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
    Gynecol Oncol, 136 (2), 224-9
    DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159
18. Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B (2014)
    APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
    Am J Clin Pathol, 142 (1), 51-7
    DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085
19. Vaksman O, Tropé C, Davidson B, Reich R (2014)
    Exosome-derived miRNAs and ovarian carcinoma progression
    Carcinogenesis, 35 (9), 2113-20
    DOI 10.1093/carcin/bgu130, PubMed 24925027
20. Vilming Elgaaen B, Olstad OK, Haug KB, Brusletto B, Sandvik L, Staff AC, Gautvik KM, Davidson B (2014)
    Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
    BMC Cancer, 14, 80
    DOI 10.1186/1471-2407-14-80, PubMed 24512620
21. Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G (2014)
    A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
    BMC Cancer, 14, 937
    DOI 10.1186/1471-2407-14-937, PubMed 25494701

Publications 2013

1. Andersen EK, Hole KH, Lund KV, Sundfør K, Kristensen GB, Lyng H, Malinen E (2013)
   Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
   Radiother Oncol, 107 (1), 117-22
   DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024
2. Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P, Australian Ovarian Cancer Study Group, Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL (2013)
   High levels of genomic aberrations in serous ovarian cancers are associated with better survival
   PLoS One, 8 (1), e54356
   DOI 10.1371/journal.pone.0054356, PubMed 23372714
3. Davidson B, Abeler VM, Førsund M, Holth A, Yang Y, Kobayashi Y, Chen L, Kristensen GB, Shih IeM, Wang TL (2013)
   Gene expression signatures of primary and metastatic uterine leiomyosarcoma
   Hum Pathol, 45 (4), 691-700
   DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798
4. Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG (2013)
   Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
   Hum Pathol, 44 (11), 2449-60
   DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953
5. Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I, European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group (2013)
   Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
   Gynecol Oncol, 131 (2), 437-44
   DOI 10.1016/j.ygyno.2013.08.014, PubMed 23994107
6. Lando M, Wilting SM, Snipstad K, Clancy T, Bierkens M, Aarnes EK, Holden M, Stokke T, Sundfør K, Holm R, Kristensen GB, Steenbergen RD, Lyng H (2013)
   Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
   J Pathol, 230 (1), 59-69
   DOI 10.1002/path.4168, PubMed 23335387
7. Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K (2013)
   Long-term outcomes after pelvic radiation for early-stage endometrial cancer
   J Clin Oncol, 31 (31), 3951-6
   DOI 10.1200/JCO.2013.48.8023, PubMed 24019546
8. Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD (2013)
   Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
   Gynecol Oncol, 131 (2), 330-5
   DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518
9. Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B (2013)
   HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
   Gynecol Oncol, 129 (2), 358-63
   DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671
10. Vaksman O, Davidson B, Tropé C, Reich R (2013)
    Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
    Hum Pathol, 44 (12), 2677-83
    DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004
11. Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF (2013)
    Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
    Hum Pathol, 44 (9), 1859-66
    DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974